Arizona startup HealthTell has raised $26 million - showing that despite the ugly PR around Theranos, single-drop-of-blood startups can still raise capital.
The Palo Alto purveyor of single-drop-of-blood diagnostics is working to keep its core mission alive. But will Theranos be able?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Alabama startup CirculoGene Theranostics has released a new liquid biopsy test for cancer monitoring - but will it stick?